|Day Low/High||122.42 / 127.49|
|52 Wk Low/High||78.90 / 128.41|
It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.
Zoetis is not averse to a little noise as investors, analysts take notice.
Shares of Valeant Pharmaceuticals were higher Monday on news that the company named a new CFO.
Valeant's new CFO Paul Herendeen is a 'solid' performer and a welcome addition to the beleaguered company, says Jim Cramer
Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.
A potential blockbuster drug deal is reportedly in the works.
The humanization of pets has sent spending soaring, which has some pet-related stock seeing major benefits.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
U.S. futures look to follow the rally by other world market as Nintendo shares soar.
CAT not going down on bearish news gets us closer to a bottom and buy recommendation.
The S&P 500 fell almost 7% in the third quarter, the worst showing in four years.
OIH's path of least resistance is down. And quick follow-ups on NKE, ZTS and FCX.
Grexit woes continue to depress prices, but SCOTUS helps hospitals.
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
Moving past resistance, there's plenty of upside potential.
In 13-F filings with the Securities and Exchange Commission, Daniel Loeb's Third Point, Soros Fund Management, and other large fund managers disclosed big stakes in Chinese e-commerce giant Alibaba.